Company intelligence / Profile preview

Celavie Biosciences LLC

Oxnard, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Completed a Phase I clinical trial for Parkinson's disease with five-year follow-up data showing no adverse effects and improvement in motor function or arrest of disease progression in five out of seven patients[5]. The company has also conducted a trial titled "Undifferentiated human fetal brain-derived stem cells grafted into putamina of parkinsonian patients is safe and moderately effective: a phase I clinical trial"[1].

Therapeutic areas: Neurology
Modalities: Neural stem cell therapyUndifferentiated allogeneic pluripotent stem cell-based therapies
Industry: Biotech

Drug pipeline

2 assets

OK99

1 more asset in the full pipeline.

Request access →

Partnerships

The California State University[1]

Beyond the preview

Go deeper on Celavie Biosciences LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celavie Biosciences LLC.

Explore the full profile